Exellent!.
Incredible!
To guide treatment decisions. As you can read they are using "Illumina technology" to look for "actionable DNA" which can be targeted by modern drugs. See here:-
https://www.bbc.co.uk/news/uk-wales-65377533
and
https://www.bbc.co.uk/news/health-68624334
In Angle's RNS announcements of 4th and 20th January Angle have discovered that both their study (RNS of 4th Jan) AND other previous studies (RNS dated 20th Jan) showed actionable DNA is sometimes found only in the circulating tumour cells (CTC's) and NOT in the blood CtDNA!! Companies like Illumina do not have a system that can catch LIVE intact cancerous tumour cells to analyse. Angle of course do. So what do you thing they will do next???
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO
Mutational signature profiles, and therapeutic targets compatible with those found in matching primary tumor samples.".
==========
What is genomic heterogeneity?
A term that describes when different gene mutations (changes) cause the same disease or condition.
=========
So the circulationg tumour cells Parsortix caught were the best samples and most like the primary tumour.......... better that Cellsearch.
========================
Genomics
Volume 114, Issue 6, November 2022, 110500
https://www.sciencedirect.com/science/article/pii/S0888754322002452
================
All IMHO.
Did not notice that. Maybe I should try posting blatant lies like you do on a regular basis!
"Molecular analysis of circulating tumour cells—biology and biomarkers"......................
Liquid biopsy and circulating tumour cells MORE AND MORE IN THE NEWS..........
https://www.nature.com/articles/nrclinonc.2013.253
I can't spare 30p at the moment.
LOL!
TwoGood2Die.
Not allowed to use your smart phone at school then now I take it?
Not me, at least today. Do you think the takeover rumours are true?
Circulating tumour cells which is needed to get the "full picture" when they don't even have a way of catching LIVE intact circulating tumour cells to test in the first place! They only offer CtDNA analysis of the general blood which can miss actionable DNA which light show up in the CTC's! To get the full picture BOTH the CTC's and the CtDNA in the blood need to be analysed.
THEY HAVE A MAJOR PROBLEM, DON'T THEY!
They need to do a deal with Angle Plc I believe!
All IMHO.
(circulating tumour cells) to the systems they sell at the moment for the DNA analysis of the general blood. Analysing the general blood can miss actionable DNA that is sometimes found in the CTC's. These systems are now starting to be used ***by the NHS*** in the UK.........................................!!!
In this article the author says "Lucci foresees that ctDNA and circulating tumor cells will be used in combination to offer the best picture of what’s happening with a cancer inside a patient.". Angle have made the same comments. See Angle Plc's RNS's dated 4th and 20th Jan.
https://www.mdanderson.org/cancerwise/liquid-biopsies--understanding-ctdna-and-circulating-tumor-cells.h00-159463212.html
To do this they need a way of capturing the CTC's. They need to be uncontaminated by the very process that catches them. When caught using Angle's Parsortix system 99% of the cancer cells are alive and intact, ideal for testing. So, to offer a system that gives the full picture they could:-
1. Do a deal with Angle Plc and offer the Parsortix machine alongside the one they sell so it catches the CTC's.
2. Re-badge the Parsortix machine so it looks like it is their tech and do the same.
3. Re-design their machine to incorporate the Parsortix tech so one machine gives the full picture. This would use the Parsortix cassette which needs to be replaced after every test thus vastly increasing revenue.
There you have it.
IMHO Angle Plc are "sitting on a gold mine". The first DNA analysis Co. that offer this "full picture" process will one step ahead of the competition.
All IMHO.
Researcher1.
EC, Newland hasn't even managed to finance the new version of P. they mooted 2 years ago! I fear AGL are toast unless he leaves.".
======================
researcher1, the UK's NHS is now starting to use liquid biopsies as we have recently found out.
In the article below the author says "Lucci foresees that ctDNA and circulating tumour cells will be used in combination to offer the best picture of what’s happening with a cancer inside a patient.". I have read the same sort of thing elsewhere. So the likes of Illiumina, Thermo Fisher, Roche etc.... have a problem don't they? They need the addition of being able to catch and analyse circulating tumour cells in addition the general blood ctdna they already offer. The race is on? The first of them that offer this will be one step ahead of the competition. Note the cancerous cells Parsortix catches are 99% alive and intact, ideal for analysis! I would not be surprised if Angle are already discussing some sort of deal. Note the RNS of 4th Jan did say they were talking to Illumina.
https://www.mdanderson.org/cancerwise/liquid-biopsies--understanding-ctdna-and-circulating-tumor-cells.h00-159463212.html
All IMHO.
See below for link.
An excellent article that includes this:-
"Lucci foresees that ctDNA and circulating tumor cells will be used in combination to offer the best picture of what’s happening with a cancer inside a patient.".
The same conclusion as many others...............
Hello Illumina, Thermo Fisher, Roche etc.... Want to use Angle's tech in your next machine for DNA analysis?
You really need the ability to catch LIVE and intact Circulating Tumour cells to test to make your offering complete, don't you. I mean, that seems to be what the experts are saying!!!!!!! Without this ability important information could be missed. See:-
https://www.mdanderson.org/cancerwise/liquid-biopsies--understanding-ctdna-and-circulating-tumor-cells.h00-159463212.html
All IMHO.
Turnover? £5,000,000 is $6,320,125 at todays rates.
$6,320,125 / $40,000 = 158 machines.
Say 4 tests a day.
4 x $300 - $1200.
$1200 x 5 - $6,000 a week for the cassettes.
$6,000 x 4 = $24,000 a month.
$24,000 x 12 = $288,000 per year.
Interesting.
The cassettes around $300 each (1 needed per test). Just googled "breast cancer cases in USA" and it says about 240,000 new cases every year so that gives some idea of the potential market. Specifically anyone with metastasized breast cancer can have their cancer analysed from a simple blood test using the Parsortix machine to catch the live cancerous cells in their blood stream. They can then be subject to various tests including the HER2 status. Of course then we have the rest of the World to add to that potential market as it's highly likely machines cleared by the USA's FDA can be used in almost any Country, it being the "gold standard". Basically the whole World is Angle's market it seems.
I wonder how sales are going? I suppose if you fork out $40,000 on a machine you will have every intention of going a lot of tests! At $300 a time that soon adds up.
All IMHO.
TwoGood2Die.
EC.
So why doesn't Newland apply for FDA approval for Parsortix 'testing' covering all major cancer groups?
==================================
Parsortix is FDA approved in the USA for catching breast cancer circulating tumour cells (CTC's) that can then be analysed to see whether they are HER2 positive, HER2 low, or HER2 negative. Also other tests to see how the treatment is going etc.. etc... The Breast cancer market is the USA a massive on it's own. It will be interesting to see how sales of the machine are going in the results. I think they are around $40,000 each and each time a test is done a cassette is needed which are around $300 each. I believe as it is approved in USA most other Countries in the World would allow it's use (FDA approval being the "gold standard").
Mr Newland envisages coming to an arrangement with Companies like EISAI INC., one of the top 100 companies in Japan that we already have a small contract with. EISAI INC. are testing their cancer drug. The persons HER2 status gives a good sign whether the drug will work OR NOT. So if the drug passes for use parsortix might need to at the cancer clinic so the most suitable people are given it. It's all in the presentation:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO.
It was because Angle discovered DNA testing circulating tumour cells (CTC's that their Parsortix machine can catch live and intact) can sometimes show actionable DNA is present even though the usual method of testing fragments of DNA in the general blood missed them. Actionable DNA being DNA that modern drugs can target for better treatment. So if the CTC's are not tested as well then drugs that target these cancerous cells will obviously not be used. Possibly life saving information.
All IMHO.
By modern drugs the Circulating tumour cells (CTC's) as well as the fragments of dead cancer cells in the general blood BOTH need to be tested. End of. Angle's Parsortix system can catch the CTC's alive and intact. Ideal for testing. The various Companies throughout the World that already offer the general DNA testing of blood obviously need to add this to their offering. Maybe it will be for the high end clients initially due to the increased cost. It is only a matter of time before these Molecular analysis Companies start to add this ability. Then they will be one step ahead of the competition being able to say their system can also check the circulating tumour cells which sometimes show the cancer has actionable DNA when the dead cell fragments in the general blood DO NOT!
All IMHO.
Here's the link:-
https://www.proactiveinvestors.co.uk/companies/news/1043762/angle-shares-up-as-nhs-move-reveals-potential-of-liquid-biopsy-systems-1043762.html